BeiGene
BGNE
#976
Rank
A$32.53 B
Marketcap
$297.36
Share price
0.49%
Change (1 day)
26.49%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$25.02

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$26.79. In 2022 the company made an earnings per share (EPS) of -$31.18 a decrease over its 2021 EPS that were of -$24.49.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$25.02-19.77%
2022-$31.1827.35%
2021-$24.49-19.96%
2020-$30.5920.81%
2019-$25.3231.52%
2018-$19.25417.57%
2017-$3.72-37.16%
2016-$5.92158.95%
2015-$2.29

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.61-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.43-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA